Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934041 | 1.00 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL22403747 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1892418 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637389 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637391 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL23017054 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637867 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15543930 | 0.92 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL21235537 | 0.92 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL25359611 | 0.92 | CNR1 (0.52) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024500-A1 | METHODS AND SYSTEMS FOR TRANSDERMAL IMMUNOTHERAPY | Passport Technologies, Inc. (US) | 2025-01-30 | — | — | WO | claimed |
| EP-2506879-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | Protiva Biotherapeutics Inc. (CA) | 2012-10-10 | — | — | EP | claimed |
| WO-2011066651-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-06-09 | — | — | WO | claimed |
| EP-3595715-B1 | RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY | CureVac SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-14 | — | — | US | disclosed |
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260091107-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260069677-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | ARCTURUS THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141704-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141705-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011075656-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011066651-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010054405-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | HLA-B, ADA, HLA-A | ALDH1A1 1766/4885CNR1 4122/4885CNR2 4512/4885 |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS1, SGMS2, PHOSPHO1 | ALDH1A1 3475/4885CNR1 656/4885CNR2 731/4885 |
| US-20260091107-A1 | CORONAVIRUS VACCINE | NSUN2, RNMT, RNGTT | ALDH1A1 4061/4885CNR1 4374/4885CNR2 4574/4885 |
| US-20260069677-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | STING1, MAVS, MYD88 | ALDH1A1 4848/4885CNR1 4655/4885CNR2 4347/4885 |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | ADAR, RNGTT, UPF1 | ALDH1A1 4716/4885CNR1 4602/4885CNR2 4694/4885 |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, OAT, POLRMT | ALDH1A1 4119/4885CNR1 4444/4885CNR2 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.